Oncternal Therapeutics Inc (ONCT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Oncternal Therapeutics Inc (ONCT) has a cash flow conversion efficiency ratio of -0.760x as of September 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.95 Million) by net assets ($9.15 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Oncternal Therapeutics Inc (ONCT) total market value for the company's overall valuation and market capitalisation.
Oncternal Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2002–2023)
This chart illustrates how Oncternal Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Oncternal Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oncternal Therapeutics Inc ranked by their cash flow conversion efficiency. Explore Oncternal Therapeutics Inc (ONCT) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lypsa Gems & Jewellery Limited
NSE:LYPSAGEMS
|
0.052x |
|
Shirpur Gold Refinery Limited
NSE:SHIRPUR-G
|
-0.008x |
|
Integrated Media Technology Ltd
NASDAQ:IMTE
|
-0.025x |
|
TNL Mediagene Ordinary Shares
NASDAQ:TNMG
|
-3.332x |
|
Arbuthnot Banking Group Plc
LSE:ARBB
|
0.304x |
|
Kaixin Auto Holdings
NASDAQ:KXIN
|
-0.028x |
|
Reach PLC
LSE:RCH
|
0.015x |
|
Golden Cross Resources Ltd
AU:GCR
|
-0.046x |
Annual Cash Flow Conversion Efficiency for Oncternal Therapeutics Inc (2002–2023)
The table below shows the annual cash flow conversion efficiency of Oncternal Therapeutics Inc from 2002 to 2023. View Oncternal Therapeutics Inc (ONCT) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $30.05 Million | $-32.16 Million | -1.070x | -77.78% |
| 2022-12-31 | $60.97 Million | $-36.70 Million | -0.602x | -99.52% |
| 2021-12-31 | $88.12 Million | $-26.59 Million | -0.302x | -94.81% |
| 2020-12-31 | $112.95 Million | $-17.50 Million | -0.155x | +86.76% |
| 2019-12-31 | $14.31 Million | $-16.75 Million | -1.170x | +22.35% |
| 2018-12-31 | $26.11 Million | $-39.35 Million | -1.507x | -145.76% |
| 2017-12-31 | $38.26 Million | $-23.46 Million | -0.613x | +41.30% |
| 2016-12-31 | $19.89 Million | $-20.78 Million | -1.045x | +90.31% |
| 2015-12-31 | $1.86 Million | $-20.04 Million | -10.777x | -568.13% |
| 2014-12-31 | $17.83 Million | $-28.76 Million | -1.613x | +60.81% |
| 2013-12-31 | $10.68 Million | $-43.97 Million | -4.116x | -429.03% |
| 2012-12-31 | $47.70 Million | $-37.11 Million | -0.778x | -68.98% |
| 2011-12-31 | $71.87 Million | $-33.09 Million | -0.460x | +21.99% |
| 2010-12-31 | $51.73 Million | $-30.53 Million | -0.590x | -111.23% |
| 2009-12-31 | $-8.75 Million | $-46.00 Million | 5.257x | +5854.26% |
| 2008-12-31 | $32.02 Million | $-2.92 Million | -0.091x | +80.84% |
| 2007-12-31 | $78.92 Million | $-37.63 Million | -0.477x | -303.85% |
| 2006-12-31 | $97.05 Million | $-11.46 Million | -0.118x | +75.05% |
| 2005-12-31 | $73.58 Million | $-34.82 Million | -0.473x | -92.99% |
| 2004-12-31 | $63.91 Million | $-15.67 Million | -0.245x | -383.43% |
| 2003-12-31 | $-150.23 Million | $-13.00 Million | 0.087x | -54.66% |
| 2002-12-31 | $-55.31 Million | $-10.55 Million | 0.191x | -- |
About Oncternal Therapeutics Inc
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS… Read more